An Extension Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Long-term Safety, Efficacy, and Durability of Response to ESK-001

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are:
* How safe is taking ESK-001 long-term in people with moderate to severe plaque psoriasis?
* Does taking ESK-001 long-term reduce the severity of people's plaque psoriasis?
Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-001 twice daily for 24 weeks. After 24 weeks, the first 200 patients meeting at least PASI-75 clinical response will be randomly assigned to receive ESK-001 or placebo. At any point during this time, the patients losing the initial clinical response may return to the open-label ESK-001 treatment. Patients who complete Week 48 will return to open-label ESK-001 treatment and they will receive ESK-001 until the end of the study or discontinuation. All the remaining patients not meeting the entry criteria for the randomized withdrawal phase will continue to receive open-label ESK-001 for the remainder of the study.
Patients taking part in the study must be men or women aged at least 18 years old and have completed a previous (parent) study of ESK-001 in moderate to severe plaque psoriasis.
Patients must consent and agree to:
* ensure drug daily compliance until end of study or discontinuation.
* visit the clinic for checkups and assessments.
* provide blood and urine samples.

开始日期2025-01-08

申办/合作机构

Alumis, Inc.初创企业

NCT06588738

/ Recruiting临床3期

A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2)

The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are:
* Does ESK-001 reduce the severity of people's psoriasis?
* How safe is ESK-001 in people with moderate to severe plaque psoriasis?
The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psoriasis).
People taking part in this study must be men or women aged at least 18 years and have had plaque psoriasis for at least 6 months, currently moderate to severe.
Participants will:
* take drug every day for 24 weeks.
* visit the clinic for checkups and tests.
* fill out questionnaires about their psoriasis, itch severity, and change in quality of life.
* be assessed for health issues and side effects, physical examinations, vital signs, heart electrical activity measurements, and psychological health.
* provide blood and urine samples.

开始日期2024-08-20

申办/合作机构

Alumis, Inc.初创企业

NCT06586112

/ Recruiting临床3期

A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis (ONWARD1)

开始日期2024-07-25

申办/合作机构

Alumis, Inc.初创企业

100 项与 FTP-637 相关的临床结果

登录后查看更多信息

100 项与 FTP-637 相关的转化医学

登录后查看更多信息

100 项与 FTP-637 相关的专利（医药）

登录后查看更多信息

项与 FTP-637 相关的文献（医药）

2023-08-01·International immunopharmacology

Recent progress on tyrosine kinase 2 JH2 inhibitors

Review

作者: Liao, Tingting ; Wu, Xianbo ; Wang, Jie ; Deng, Lidan ; Wang, Lin ; Wan, Li ; Shi, Jianyou

Tyrosine kinase 2 (TYK2) is a member of the Janus kinase (JAK) family, which can regulate the signaling of multiple pro-inflammatory cytokines, including IL12, IL23 and type I interferon (IFNα/β), and its inhibitors can treat autoimmune diseases caused by the abnormal expression of IL12 and IL23. Interest in TYK2 JH2 inhibitors has increased as a result of safety concerns with JAK inhibitors. This overview introduces TYK2 JH2 inhibitors that are already on the market, including Deucravactinib (BMS-986165), as well as those currently in clinical trials, such as BMS-986202, NDI-034858, and ESK-001.

2023-04-13·Journal of medicinal chemistry1区 · 医学

Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors.

1区 · 医学

Review

作者: Zhang, Xiangyu ; Wang, Tianyu ; Zhang, Kuojun ; Ye, Ke ; Qi, Zhihao ; Mao, Jie ; Jiang, Sheng ; Tang, He

Janus kinases (JAKs) are central components in cytokine signaling pathways. A number of small molecule JAK inhibitors have been approved to treat a wide range of inflammatory and autoimmune diseases. Due to safety concerns of pan-JAK inhibition, the thrust of current research is toward the discovery of isoform-selective JAK inhibitors. Selective inhibition of tyrosine kinase 2 (TYK2) has the potential to balance efficacy and safety. Substantial efforts have been made to develop selective TYK2 inhibitors: Deucravacitinib (BMS-986165) is a representative allosteric inhibitor that has been approved by the FDA, and ropsacitinib (PF-06826647) is an active site-directed inhibitor currently being evaluated in clinical trials. Herein, we outline the key roles of TYK2 in diseases, review the advances of selective TYK2 inhibitors, and finally discuss future perspectives and challenges in the development of TYK2 inhibitors.

2023-01-01·Journal of cutaneous medicine and surgery

Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway

Review

作者: Turchin, Irina ; Grewal, Parbeer ; Hong, Chih-Ho ; Papp, Kim A ; Loo, Wei Jing ; Prajapati, Vimal H ; Maari, Catherine ; Gooderham, Melinda J ; Vender, Ronald B ; Sauder, Maxwell

Cytokines in the interleukin (IL)−23/IL-17 axis are central to psoriasis pathogenesis. Janus kinase (JAK) signal transducer and activator of transcription (STAT) regulates intracellular signalling of several cytokines (including IL-12, 23, 22, 6, 17, and interferon (IFN)-γ) in the IL-23/IL-17 axis, and, as a result, has become a therapeutic target for psoriasis treatment. Although several JAK1-3 inhibitors, with varying degrees of selectivity, have been developed for immune-mediated inflammatory diseases, use in psoriasis is limited by a low therapeutic index as anticipated by signals from other disease indications. More selective inhibition of the JAK family is an area of interest. Specifically, selective tyrosine kinase (TYK)2 inhibition suppresses IL-23/IL-17 axis signalling, and at therapeutic doses, has a favorable safety profile compared to therapeutic doses of JAK1-3 inhibitors. Phase III efficacy and safety data for the selective allosteric TYK2-inhibitor, deucravacitinib, in adult patients with moderate-to-severe plaque psoriasis is promising. Furthermore, phase II clinical trials for ropsacitinib (PF-06826647), a selective TYK2 inhibitor, and brepocitinib (PF-06700841), a JAK1/TYK2 inhibitor, have also demonstrated efficacy and an acceptable safety profile in adult patients with moderate-to-severe plaque psoriasis. Other novel TYK2 allosteric inhibitors, NDI-034858 and ESK-001, are currently being investigated in adult patients with plaque psoriasis. This article reviews the details of the JAK-STAT pathway in psoriasis pathophysiology, the rationale for selective targeting of JAKs in the treatment of psoriasis, and provides clinical perspective on clinical trial data for JAK and TYK2 inhibitors.

102

项与 FTP-637 相关的新闻（医药）

2025-03-29

·医药地理

一周药讯：国家卫健委等7部门发布《2023年度全国三级公立医院绩效监测分析情况通报》

扫描二维码即可下载《数图药讯》2025年3月第13期目录行业政策1.国家卫健委：发布《中华人民共和国生物安全法》《中华人民共和国人类遗传资源管理条例》《人类遗传资源管理条例实施细则》2.国家药监局、国家卫健委：关于颁布2025年版《中华人民共和国药典》的公告（2025年第29号）3.国家卫健委、国家医保局等七部门：关于印发2023年度全国三级公立医院绩效监测分析情况的通报4.天津市医保局：关于完善我市门诊特定疾病药品保障范围的通知5.四川省卫健委、四川省医保局等五部门：关于推动支持创新药临床应用的通知6.内蒙古自治区医药采购网：关于开展医院联盟药品议价采购试点工作相关药品信息填报的通知7.江西省医保局：关于印发《江西省国家医保谈判药品“双通道”管理办法》的通知行业动态1. 药讯动态：重磅获批2. 药讯动态：重磅临床3. 药企动态：市场动态零售行业动态多地门诊统筹药店，取消“城乡起付线”本周总结政策解读1、国家卫健委：发布《中华人民共和国生物安全法》《中华人民共和国人类遗传资源管理条例》《人类遗传资源管理条例实施细则》《中华人民共和国生物安全法》《中华人民共和国人类遗传资源管理条例》及《人类遗传资源管理条例实施细则》的发布，旨在加强生物安全管理，规范人类遗传资源的采集、保藏、利用和对外提供，保障公众健康，维护国家生物安全和人类遗传资源安全。附件：1.中华人民共和国生物安全法.pdf2.中华人民共和国人类遗传资源管理条例.pdf3.人类遗传资源管理条例实施细则.pdf相关文件请扫描上方二维码查看2、国家药监局、国家卫健委：关于颁布2025年版《中华人民共和国药典》的公告（2025年第29号）根据《中华人民共和国药品管理法》，2025年版《中华人民共和国药典》（以下简称《中国药典》）经第十二届药典委员会执行委员会全体会议审议通过，现予颁布，自2025年10月1日起施行。2025年版《中国药典》目录见附件。特此公告。附件：1.2025年版《中国药典》一部目录.pdf2.2025年版《中国药典》二部目录.pdf3.2025年版《中国药典》三部目录.pdf4.2025年版《中国药典》四部目录.pdf相关文件请扫描上方二维码查看3、国家卫健委、国家医保局等七部门：关于印发2023年度全国三级公立医院绩效监测分析情况的通报按照《国务院办公厅关于加强三级公立医院绩效考核工作的意见》（国办发〔2019〕4号，以下简称《意见》）要求，国家卫生健康委联合相关部门，根据三级公立医院绩效监测指标数据，对全国三级公立医院开展了监测分析，形成三级公立医院绩效监测分析情况通报，现印发给你们。各部门、各有关医院要认真落实《意见》要求，扎实推进公立医院绩效监测工作，做好本辖区监测指标数据的对比分析，以问题和需求为导向，不断提升公立医院的科学管理水平和医疗服务能力，不断完善公立医院综合改革的各项政策措施，并抓好落实。具体信息请登录国家卫健委官网查看。4、天津市医保局：关于完善我市门诊特定疾病药品保障范围的通知为做好门诊特定疾病保障，依据《天津市基本医疗保险条例》、《关于建立待遇清单制度的通知》等政策规定，结合本市实际，现就完善我市门诊特定疾病药品保障范围有关事项通知如下。具体信息请登录天津市医保局官网查看。附件：1.《国家基本医疗保险、工伤保险和生育保险药品目录》凡例.pdf2.《国家基本医疗保险、工伤保险和生育保险药品目录》西药部分.pdf3.《国家基本医疗保险、工伤保险和生育保险药品目录》中成药部分.pdf4.《国家基本医疗保险、工伤保险和生育保险药品目录》协议期内谈判药品部分（含竞价药品）.pdf相关文件请扫描上方二维码查看5、四川省卫健委、四川省医保局等五部门：关于推动支持创新药临床应用的通知四川省卫健委等五部门联合下发《关于推动支持创新药临床应用的通知》（川卫药物食品函〔2025〕64号），在畅通创新药入院流程、强化创新药临床应用，打造创新药临床应用场景等九个方面做出政策安排。具体信息请登录四川省卫健委官网查看。6、内蒙古自治区医药采购网：关于开展医院联盟药品议价采购试点工作相关药品信息填报的通知为做好医院联盟药品议价采购试点工作，根据《关于开展医院联盟药品议价采购试点工作的实施方案》，开展相关药品信息填报工作，现将有关事宜通知如下。具体信息请登录内蒙古自治区医药采购网官网查看。附件：1.药品填报范围.xlsx2.企业递交资质材料要求及相关模板.doc相关文件请扫描上方二维码查看7、江西省医保局：关于印发《江西省国家医保谈判药品“双通道”管理办法》的通知为进一步提升国家医保谈判药品供应保障水平，更好地保障我省参保人员利益，提高国家医保谈判药品的可及性，维护医保基金安全，根据有关政策要求，我们修订了《江西省国家医保谈判药品“双通道”管理办法》，现印发给你们，请遵照执行。具体信息请登录江西省医保局官网查看。行业动态01药讯动态：重磅获批最近重磅获批江西科睿药业申报的1类创新药玛舒拉沙韦片获得NMPA批准上市，该药适用于既往健康的12岁及以上青少年和成人单纯性甲型和乙型流感患者的治疗，不包括存在流感相关并发症高风险的患者。君实生物自主研发的抗PD-1单抗药物特瑞普利单抗获得HSA批准上市，联合顺铂和吉西他滨用于复发、不能手术或放疗的，或转移性鼻咽癌成人患者的一线治疗。施维雅（Servier）申报的5.1类新药艾伏尼布片的新适应症上市申请获得CDE受理，申报上市的适应症可能为联合阿扎胞甘一线治疗携带易感IDH1突变的AML患者。GSK自主研发的“first-in-class”抗生素Blujepa（gepotidacin）获得FDA批准上市，用于治疗单纯性尿路感染（uUTI）的成人及12岁以上青少年患者。Alnylam公司的Amvuttra（vutrisiran）获得FDA批准，成为首款治疗伴有心肌病的转甲状腺素蛋白淀粉样变性（ATTR-CM）成人患者的siRNA疗法。02药讯动态：重磅临床最近重磅临床Alexion公司申报的1类新药eneboparatide注射液获得CDE批准临床，拟开发治疗慢性甲状旁腺功能减退症。礼来（Eli Lilly and Company）申报的1类新药注射用LY4052031获得CDE批准临床，拟单药用于治疗晚期或转移性尿路上皮癌或其他实体瘤。华东医药自主研发的1类新药HDM3019获得CDE批准临床，拟开发治疗类风湿关节炎。复宏汉霖申报的人唾液酸酶融合蛋白HLX79注射液（E-602）Ⅱ期临床试验申请获NMPA临床试验批准，联合汉利康（利妥昔单抗）治疗活动期肾小球肾炎。科伦博泰1类新药SKB107注射液获得CDE批准临床，拟开发用于晚期实体瘤骨转移。映恩生物自组研发的1类新药注射用DB-2304获得CDE批准临床，拟开发治疗系统性红斑狼疮。 03药企动态：市场动态3月24日，联邦制药宣布旗下全资子公司联邦生物已与诺和珠海订立独家许可协议，将UBT251的海外权益授予诺和诺德。根据独家许可协议，诺和诺德将获得UBT251的全球（不包括中国大陆、香港特别行政区、澳门特别行政区和台湾）开发、生产和商业化权益。联邦生物将保留UBT251的中国权益。3月25日，恒瑞医药刚刚宣布与默沙东（MSD）就其脂蛋白(a)[Lp(a)]口服小分子项目（包括名为HRS-5346的先导化合物）达成独家许可协议。根据协议条款，恒瑞医药将HRS-5346在大中华区以外的全球范围内开发、生产和商业化的独家权利有偿许可给默沙东。恒瑞医药将收取2亿美元的首付款，并有资格获得不超过17.7亿美元的与特定的开发、监管和商业化相关的里程碑付款，以及如果相关产品获批上市，基于HRS-5346的净销售额的销售提成。3月25日，Alumis 制药公司与 Kaken 制药公司宣布了一项合作与许可协议，共同在日本开发和商业化 Alumis 的 ESK-001，这是一种用于皮肤病适应症的口服 TYK2 抑制剂。根据协议条款，Alumis将获得4000万美元的预付款和近期共同开发款项，未来还有可能获得约1.4亿美元的额外里程碑付款和领域选择付款，以及未来ESK-001在日本净销售额的分级特许权使用费。零售行业动态01多地门诊统筹药店，取消“城乡起付线”普通门诊统筹基金保障参保人员，符合规定的医疗费用不设起付标准，职工医保在职人员年度最高支付限额为2723元，退休人员为2996元，居民医保参保人为2179元。医保支付比例按医疗机构级别划分，一级医疗卫生机构及一级以下非营利性机构支付比例最高，为90%；其他一级以下机构职工医保为60%，居民医保为50%。参保人患常见小病可优先选择医保定点基层医疗机构，报销比例更高。此外，佛山市普通门诊统筹执行广东省基本医疗保险药品、诊疗项目、医用耗材目录及相关支付标准。具体信息请登录广东省佛山市医保局官网查看。本周总结行业政策国家卫健委发布《中华人民共和国生物安全法》《中华人民共和国人类遗传资源管理条例》《人类遗传资源管理条例实施细则》；国家药监局与国家卫健委联合颁布2025年版《中华人民共和国药典》，自2025年10月1日起施行；国家卫健委等七部门印发《2023年度全国三级公立医院绩效监测分析情况的通报》，强调提升公立医院管理水平和医疗服务能力；天津市医保局完善门诊特定疾病药品保障范围；四川省卫健委等五部门发布通知，推动创新药临床应用；内蒙古自治区医药采购网开展医院联盟药品议价采购试点工作等。行业动态新药研发与获批进展显著。江西科睿、君实生物、施维雅等多款药物获批或受理，用于治疗流感、鼻咽癌、尿路感染等疾病；Alexion、礼来的、华东医药等多款新药获CDE批准开展临床试验，涉及类风湿关节炎、系统性红斑狼疮等领域；联邦制药与诺和诺德达成独家许可协议；恒瑞医药与默沙东就Lp(a)口服小分子项目达成独家许可协议；Alumis制药与Kaken制药合作开发皮肤病口服TYK2抑制剂ESK-001。零售动态多地门诊统筹药店取消“城乡起付线”，普通门诊统筹基金保障参保人员医疗费用，不设起付标准，医保支付比例按医疗机构级别划分，基层医疗机构报销比例最高。来源：由中国医药工业信息中心整理END如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001

申请上市带量采购医药出海核酸药物

2025-03-27

·生物制药小编

来自中国药企管线，一个区权益卖了4000万美元

近日，Alumis与日本制药公司Kaken达成了合作及许可协议，共同推进其口服TYK2抑制剂ESK-001在日本的开发。为此，Alumis将获得Kaken的4000万美元的预付款，以及可能高达1.4亿美元的里程碑付款。引自中国药企的管线 ESK-001是一种高选择性口服TYK2抑制剂，旨在纠正多种促炎介质驱动疾病的免疫失调。 ESK-001目前已经处于临床Ⅲ期阶段，用于治疗中度至重度斑块状银屑病。在此前的AAD大会上，Alumis公布了ESK-001 52周的随访数据，试验结果显示，40mg剂量ESK-001组中，ASI 90（PASI评分降低90%）缓解率达到61.3%，PASI 100（PASI评分降低100%）达到38.8%，sPGA 0达到38.8%。此外，81.3%的患者在瘙痒控制方面取得显著改善（NRS评分≤4），61.3%的患者生活质量得到显著改善（DLQI 0/1）。 ESK-001耐受性良好，安全性与之前报告的16周和28周数据一致。这条管线源自中国药企海思科，2021年3月，海思科旗下子公司FT集团以6000万美元首付+以及1.2亿美元里程碑，将旗下ESK-001的所属专利和权益转让给FL2021-001公司（Alumis的前身）。也是这条管线，养活了整个公司。凭借ESK-001，Alumis十分获投资者的青睐，在3年时间累计融资5.29亿美元（不含IPO），在2021年5月、2022年1月、2024年3月，公司分别完成了7000万美元A轮融资、2亿美元B轮融资，2.59亿美元的C轮融资。并且在2024年完成C轮融资后的3个月，公司就在纳斯达克交易市场上市，募资了近2.1亿美元。目前，除了获得6000万美元首付款以外，海思科还在2022年19月获得了第一笔里程碑付款，预计海思科在2024年下半年将收到第二笔里程碑付款（约1284.32万美元）。正在谋求合并不过，市场对Alumis的支持不知为何也撤的很快，公司股价从最高点跌至4美元，市值缩水了76%。今年2月6日，Alumis与另外一家Acelyrin达成合并协议，合并后的公司将继续以Alumis的名称运营，并由Alumis的原有管理团队领导。交易预计将于今年第二季度完成。除了ESK-001之外，Alumis还有一款TYK2抑制剂A-005，这是一种中枢神经系统渗透性变构TYK2抑制剂，目前处于临床Ⅰ期阶段，用于治疗神经炎症和神经退行性疾病。合并后，Acelyrin增加了一条管线在研lonigutamab，这是一种靶向IGF-1R单抗，目前在甲状腺眼病中进行临床Ⅱ期试验。最新公布的II期临床试验结果显示，lonigutamab在TED的眼球突出、临床活动性评分、以及Graves眼病生活质量量表都有临床意义的改善。基于该表现，公司即将开展III期临床试验。参考出处: https://investors.alumis.com/static-files/babda627-0569-477c-a68f-bbe61d8fa12d国产原研分子，转手融了5.29亿美金

临床3期引进/卖出临床2期IPO临床1期

2025-03-25

·FierceBiotech

Kaken agrees to $180M deal to develop Alumis\' lead TYK2 inhibitor in Japan

Tokyo-based Kaken Pharmaceutical has committed $40 million in upfront and near-term co-development payments over this year and 2026.\n Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 (TYK2) inhibitor as a dermatology treatment in Japan.The drug in question, dubbed ESK-001, is Alumis’ lead candidate and is designed to correct immune dysregulation in diseases driven by proinflammatory mediators, including well-known targets like IL-23, IL-17, and type 1 interferon. Alumis has already been evaluating the twice-daily modified-release oral formulation in a pair of phase 3 trials in adults with moderate to severe plaque psoriasis.Alongside that late-stage program, Alumis is also running a phase 2b trial of ESK-001 in patients with systemic lupus erythematosus, which is expected to read out next year. The biotech said it “continues to leverage its precision data analytics platform to explore ESK-001’s potential application in other immune-mediated conditions” and is also working on a once-daily formulation.Tuesday morning\'s deal sees Tokyo-based Kaken commit $40 million in upfront and near-term codevelopment payments over this year and next, with the potential to pay up to $140 million in further milestone payments and field option payments as well as tiered royalties.In return, Kaken has the rights to ESK-001 as a dermatology drug in Japan and will be responsible for clinical and regulatory development along with commercialization in the country. There is also the option for Kaken to expand the licensing deal to cover rheumatological and gastrointestinal diseases. “We strongly believe in the potential of ESK-001 to address a range of medical needs in the dermatology space and potentially rheumatological and gastrointestinal diseases in the future,” Hiroyuki Horiuchi, president and representative director of Kaken, said in the March 25 release.Kaken markets a number of products in Japan, including hyaluronate sodium for osteoarthritis and Fiblast for skin ulcers. The company has also licensed a number of drugs from other companies, including seladelpar for primary biliary cholangitis from CymaBay Therapeutics and tildacerfont from Spruce Biosciences for congenital adrenal hyperplasia.“ESK-001 will be an important addition to the Kaken portfolio of novel therapeutics for dermatology conditions,” Horiuchi added in the release.Immune-mediated disease specialist Alumis is currently in the process of buying Acelyrin. Alumis’ pipeline is headed up by ESK-001, with the company sharing phase 2 data a year ago that showed the drug met its primary endpoint of the proportion of patients achieving a 75% improvement in the psoriasis area and severity score at Week 12 compared to placebo.“This partnership builds on the positive phase 2 clinical data of ESK-001, our next-generation oral TYK2 inhibitor, supporting our objectives to unlock its full therapeutic potential and ensure ESK-001 is widely accessible to people with immune-mediated disorders around the world,” Alumis CEO Martin Babler said in this morning’s release.

$Kaken agrees to $180M deal to develop Alumis\' lead TYK2 inhibitor in Japan$

临床2期引进/卖出临床3期临床结果免疫疗法

100 项与 FTP-637 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
头皮银屑病	临床3期	美国	Alumis, Inc.初创企业	2025-01-08
头皮银屑病	临床3期	加拿大	Alumis, Inc.初创企业	2025-01-08
斑块状银屑病	临床3期	美国	Alumis, Inc.初创企业	2024-07-25
斑块状银屑病	临床3期	日本	Alumis, Inc.初创企业	2024-07-25
斑块状银屑病	临床3期	澳大利亚	Alumis, Inc.初创企业	2024-07-25
斑块状银屑病	临床3期	保加利亚	Alumis, Inc.初创企业	2024-07-25
斑块状银屑病	临床3期	加拿大	Alumis, Inc.初创企业	2024-07-25
斑块状银屑病	临床3期	捷克	Alumis, Inc.初创企业	2024-07-25
斑块状银屑病	临床3期	德国	Alumis, Inc.初创企业	2024-07-25
斑块状银屑病	临床3期	波兰	Alumis, Inc.初创企业	2024-07-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


GlobeNewswire 人工标引	临床2期	斑块状银屑病	-	ESK-001	願網夢網鹽醖鏇淵築齋(選構壓齋餘醖衊憲鏇鑰) = 壓繭遞觸築範築艱廠艱網積鏇獵繭鑰膚鏇顧願 (醖鏇憲憲夢顧鹹醖襯構 ) 达到更多	积极	2024-11-13
NCT05600036 (STRIDE, GlobeNewswire) 人工标引	临床2期	银屑病	-	ESK-001 40 mg twice daily (STRIDE Week 12 + NRI)	膚網範廠窪鏇廠鹽選淵(網積繭艱遞艱艱積繭廠) = 鹽衊遞鑰壓觸醖範淵鏇獵獵範淵壓觸醖齋醖醖 (衊構繭範鹽觸糧窪鹽淵 ) 更多	积极	2024-09-27
				ESK-001 40 mg twice dailyESK-001 40 mg twice daily (OLE Week 28 + AO)	膚網範廠窪鏇廠鹽選淵(網積繭艱遞艱艱積繭廠) = 築膚網鹹淵醖積鹽繭糧獵獵範淵壓觸醖齋醖醖 (衊構繭範鹽觸糧窪鹽淵 ) 更多
NCT05600036 (STRIDE, CTgov)	临床2期	斑块状银屑病	228	Placebo	淵窪簾範廠壓構醖廠蓋 = 網齋範夢憲鹽網願築築淵襯醖繭鏇餘糧壓窪鹽 (廠鏇繭顧蓋簾鹽鹹選範, 積餘觸願鹽鏇觸憲艱窪 ~ 獵鏇壓繭齋艱窪鬱憲鹽) 更多	-	2024-07-23
NCT05600036 (STRIDE, GlobeNewswire) 人工标引	临床2期	-	228	ESK-001 10 mg QD	觸範製製衊觸衊顧壓構(願選夢繭製製製夢憲顧) = 襯鹹獵餘壓襯醖膚衊築餘鹹齋築範鑰積積簾遞 (鬱鑰窪鬱襯鏇艱鹹繭窪 ) 达到更多	积极	2024-03-09
				ESK-001 20 mg QD	觸範製製衊觸衊顧壓構(願選夢繭製製製夢憲顧) = 鏇範繭鬱鏇糧淵艱廠窪餘鹹齋築範鑰積積簾遞 (鬱鑰窪鬱襯鏇艱鹹繭窪 ) 达到更多
NCT05739435 (GlobeNewswire) 人工标引	临床2期	-	164	ESK-001 (evaluable patients)	顧膚鹹廠鏇憲鑰簾簾膚(壓衊艱鑰齋壓鏇鬱憲製) = 壓顧鹹齋襯獵繭鬱製衊網網鹹鏇製遞糧觸觸範 (築繭淵憲糧獵選選網夢 ) 更多	积极	2024-03-09
				ESK-001 (non-responder imputation)	顧膚鹹廠鏇憲鑰簾簾膚(壓衊艱鑰齋壓鏇鬱憲製) = 襯餘製壓醖構網鑰鹽鬱網網鹹鏇製遞糧觸觸範 (築繭淵憲糧獵選選網夢 ) 更多